163 related articles for article (PubMed ID: 22666589)
1. Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?
Mileshkin L; Shah B; Michael M
Chemother Res Pract; 2012; 2012():838509. PubMed ID: 22666589
[TBL] [Abstract][Full Text] [Related]
2. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
4. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
[TBL] [Abstract][Full Text] [Related]
5. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues.
Sebti SM; Hamilton AD
Expert Opin Investig Drugs; 2000 Dec; 9(12):2767-82. PubMed ID: 11093352
[TBL] [Abstract][Full Text] [Related]
6. Clinical testing for molecular targets for personalized treatment in lung cancer.
Lam DC
Respirology; 2013 Feb; 18(2):233-7. PubMed ID: 22957484
[TBL] [Abstract][Full Text] [Related]
7. Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside.
Ben-Shlomo A; Cooper O
Curr Opin Endocrinol Diabetes Obes; 2017 Aug; 24(4):301-305. PubMed ID: 28520590
[TBL] [Abstract][Full Text] [Related]
8. The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
Demurtas L; Puzzoni M; Giampieri R; Ziranu P; Pusceddu V; Mandolesi A; Cremolini C; Masi G; Gelsomino F; Antoniotti C; Loretelli C; Meriggi F; Zaniboni A; Falcone A; Cascinu S; Scartozzi M
Br J Cancer; 2017 Jul; 117(3):315-321. PubMed ID: 28632725
[TBL] [Abstract][Full Text] [Related]
9. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.
Kalikaki A; Koutsopoulos A; Trypaki M; Souglakos J; Stathopoulos E; Georgoulias V; Mavroudis D; Voutsina A
Br J Cancer; 2008 Sep; 99(6):923-9. PubMed ID: 19238633
[TBL] [Abstract][Full Text] [Related]
10. From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer.
Dimou A; Harrington K; Syrigos KN
Patholog Res Int; 2011; 2011():312346. PubMed ID: 21785682
[TBL] [Abstract][Full Text] [Related]
11. Somatic mutations and immune checkpoint biomarkers.
Parris BA; Shaw E; Pang B; Soong R; Fong K; Soo RA
Respirology; 2019 Mar; 24(3):215-226. PubMed ID: 30636374
[TBL] [Abstract][Full Text] [Related]
12. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.
Scartozzi M; Giampieri R; Maccaroni E; Mandolesi A; Giustini L; Silva R; Zaniboni A; Biscotti T; Biagetti S; Galizia E; Loupakis F; Falcone A; Bearzi I; Cascinu S
Ann Oncol; 2012 Jul; 23(7):1706-12. PubMed ID: 22112971
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas.
Van Damme N; Deron P; Van Roy N; Demetter P; Bols A; Van Dorpe J; Baert F; Van Laethem JL; Speleman F; Pauwels P; Peeters M
BMC Cancer; 2010 May; 10():189. PubMed ID: 20459770
[TBL] [Abstract][Full Text] [Related]
14. The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside.
Zaniboni A; Formica V
Cancer Chemother Pharmacol; 2016 Aug; 78(2):233-44. PubMed ID: 27091467
[TBL] [Abstract][Full Text] [Related]
15. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
[TBL] [Abstract][Full Text] [Related]
16. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
O'Byrne KJ; Gatzemeier U; Bondarenko I; Barrios C; Eschbach C; Martens UM; Hotko Y; Kortsik C; Paz-Ares L; Pereira JR; von Pawel J; Ramlau R; Roh JK; Yu CT; Stroh C; Celik I; Schueler A; Pirker R
Lancet Oncol; 2011 Aug; 12(8):795-805. PubMed ID: 21782507
[TBL] [Abstract][Full Text] [Related]
17. Tumour genetics and genomics to personalise cancer treatment.
Voon PJ; Kong HL
Ann Acad Med Singap; 2011 Aug; 40(8):362-8. PubMed ID: 22065002
[TBL] [Abstract][Full Text] [Related]
18. Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing?
Kim L; Tsao MS
Eur Respir J; 2014 Oct; 44(4):1011-22. PubMed ID: 25102961
[TBL] [Abstract][Full Text] [Related]
19. Improvement in the quality of molecular analysis of EGFR in non-small-cell lung cancer detected by three rounds of external quality assessment.
Deans ZC; Bilbe N; O'Sullivan B; Lazarou LP; de Castro DG; Parry S; Dodson A; Taniere P; Clark C; Butler R
J Clin Pathol; 2013 Apr; 66(4):319-25. PubMed ID: 23378269
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
